{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:00:29Z","timestamp":1758636029171},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2011,4,15]],"date-time":"2011-04-15T00:00:00Z","timestamp":1302825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,4,15]],"date-time":"2011-04-15T00:00:00Z","timestamp":1302825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1038\/leu.2011.69","type":"journal-article","created":{"date-parts":[[2011,4,15]],"date-time":"2011-04-15T08:42:19Z","timestamp":1302856939000},"page":"1168-1173","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet"],"prefix":"10.1038","volume":"25","author":[{"given":"M","family":"\u00d8stergaard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C G","family":"Nyvold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J V","family":"Jovanovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M T","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Kairisto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y G","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Tobal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Pallisgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U","family":"\u00d6zbek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Pfeifer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Schnittger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Grubach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J K","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Grimwade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Hokland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,4,15]]},"reference":[{"key":"BFleu201169_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1046\/j.1365-2141.1999.01629.x","volume":"106","author":"DK Webb","year":"1999","unstructured":"Webb DK . Management of relapsed acute myeloid leukaemia. Br J Haematol 1999; 106: 851\u2013859.","journal-title":"Br J Haematol"},{"key":"BFleu201169_CR2","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1053\/j.seminoncol.2008.04.009","volume":"35","author":"SD Freeman","year":"2008","unstructured":"Freeman SD, Jovanovic JV, Grimwade D . Development of minimal residual disease-directed therapy in acute myeloid leukemia. Semin Oncol 2008; 35: 388\u2013400.","journal-title":"Semin Oncol"},{"key":"BFleu201169_CR3","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/sj.leu.2403309","volume":"18","author":"VH van der Velden","year":"2004","unstructured":"van der Velden VH, Boeckx N, Gonzalez M, Malec M, Barbany G, Lion T et al. Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease--a study within the Europe Against Cancer Program. Leukemia 2004; 18: 884\u2013886.","journal-title":"Leukemia"},{"key":"BFleu201169_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/sj.leu.2404983","volume":"22","author":"MC Muller","year":"2008","unstructured":"Muller MC, Erben P, Saglio G, Gottardi E, Nyvold CG, Schenk T et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia 2008; 22: 96\u2013102.","journal-title":"Leukemia"},{"key":"BFleu201169_CR5","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","volume":"17","author":"J Gabert","year":"2003","unstructured":"Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe Against Cancer program. Leukemia 2003; 17: 2318\u20132357.","journal-title":"Leukemia"},{"key":"BFleu201169_CR6","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1200\/JCO.2009.22.4865","volume":"27","author":"D Cilloni","year":"2009","unstructured":"Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 2009; 27: 5195\u20135201.","journal-title":"J Clin Oncol"},{"key":"BFleu201169_CR7","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","volume":"17","author":"E Beillard","year":"2003","unstructured":"Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u2018real-time\u2019 quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)\u2014a Europe Against Cancer program. Leukemia 2003; 17: 2474\u20132486.","journal-title":"Leukemia"},{"key":"BFleu201169_CR8","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","volume":"17","author":"JJ van Dongen","year":"2003","unstructured":"van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257\u20132317.","journal-title":"Leukemia"},{"key":"BFleu201169_CR9","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1038\/leu.2009.168","volume":"23","author":"MC Muller","year":"2009","unstructured":"Muller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009; 23: 1957\u20131963.","journal-title":"Leukemia"},{"key":"BFleu201169_CR10","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/sj.leu.2402922","volume":"17","author":"VH van der Velden","year":"2003","unstructured":"van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ . Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003; 17: 1013\u20131034.","journal-title":"Leukemia"},{"key":"BFleu201169_CR11","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402\u2013408.","journal-title":"Methods"},{"key":"BFleu201169_CR12","first-page":"85","volume":"25","author":"PC Nowell","year":"1960","unstructured":"Nowell PC, Hungerford DA . Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960; 25: 85\u2013109.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu201169_CR13","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1200\/JCO.2008.20.1533","volume":"27","author":"D Grimwade","year":"2009","unstructured":"Grimwade D, Jovanovic JV, Hills RK, Nugent EA, Patel Y, Flora R et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 2009; 27: 3650\u20133658.","journal-title":"J Clin Oncol"},{"key":"BFleu201169_CR14","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1182\/blood-2009-03-213389","volume":"114","author":"S Schnittger","year":"2009","unstructured":"Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 2009; 114: 2220\u20132231.","journal-title":"Blood"},{"key":"BFleu201169_CR15","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1182\/blood-2008-08-173674","volume":"114","author":"RD Press","year":"2009","unstructured":"Press RD, Willis SG, Laudadio J, Mauro MJ, Deininger MW . Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood 2009; 114: 2598\u20132605.","journal-title":"Blood"},{"key":"BFleu201169_CR16","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/sj.leu.2404637","volume":"21","author":"WC Chou","year":"2007","unstructured":"Chou WC, Tang JL, Wu SJ, Tsay W, Yao M, Huang SY et al. Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Leukemia 2007; 21: 998\u20131004.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201169","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T14:09:34Z","timestamp":1648735774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,15]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["BFleu201169"],"URL":"https:\/\/doi.org\/10.1038\/leu.2011.69","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,15]]},"assertion":[{"value":"6 September 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JKL is an employee at Langtved Data, who received financial support from the European LeukemiaNet (WP12) to develop the program. None of the other authors have financial relations to the company. All ELN WP12 members have the right to use the program. The program is owned by Langtved Data Ltd, which has made an agreement with ELN to further develop it and to commercialize it to non-ELN participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}